{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-118535","form_type":"8-K","ticker":"ELOX","cik":"0001035354","company_name":"Eloxx Pharmaceuticals, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.336582+00:00","generated_at":"2026-06-21T19:16:00.398981+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Eloxx Q3 net loss $7.5M ($0.09/share); Alport Phase 2 trial started, CF combo misses endpoints","bullets":["Net loss of $7.5M vs $9.9M in prior-year quarter; R&D expense $4.9M, G&A $2.3M.","Cash $24.6M as of Sep 30, 2022; expects funding into Q4 2023 subject to covenant compliance.","Phase 2 Alport trial (NCT05448755) dosed first patient; topline results expected H1 2023.","Phase 2 CF combination (ELX-02 + ivacaftor) did not meet efficacy endpoints; path forward to be determined with CF Foundation.","ZKN-013 IND for RDEB on track for end of 2022 / early 2023; preclinical data presented for TURBO-ZM platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-118535","json":"https://secwatch.observer/filing/0001104659-22-118535.json","markdown":"https://secwatch.observer/filing/0001104659-22-118535.md","text":"https://secwatch.observer/filing/0001104659-22-118535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/0001104659-22-118535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/tm2230297d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:16:00.398981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f4eeff1bc2e6c64f12d5768f2197769d6b5f29e9","claim":"Eloxx Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: net income net loss of $7.5 million, or $0.09 per share, EPS $0.09 per share.","evidence_excerpt":"For the three months ended September 30, 2022, we incurred a net loss of $7.5 million, or $0.09 per share, which included $0.7 million in stock-based compensation.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1035354/000110465922118535/0001104659-22-118535-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"net loss of $7.5 million, or $0.09 per share"},{"label":"EPS","value":"$0.09 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}